SLU-PP-332
Exercise mimetic.
- Sizes available
- —
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
ERRα agonist. Exercise mimetic, body fat research (pre-clinical).
Mechanism · Pan-ERR (Estrogen-Related Receptor) agonist. Small molecule. Note: not peptide.
Best for. Not for.
Best for
- Pre-clinical exercise-mimetic research framing
- Pan-ERR agonist mechanism users interested in
- Note: small molecule, NOT peptide. Research classification disclosure
Not for
- Users requiring human clinical evidence. Animal stage only
- Pregnancy / pregnancy
- FDA / EMA approval not established. Research-only
- Self-administered weight-loss attempts (human dosing not established)
Mechanism, dose, ramp, risk.
- Mechanism
- Pan-ERR agonist. Pre-clinical exercise-mimetic.Source · PEPVERA editorial
- Target dose
- Research-only.Source · PEPVERA editorial
- Ramp
- Slow.Source · PEPVERA editorial
- Risks
- Pre-clinical.Source · PEPVERA editorial
Compared to its siblings.
SLU-PP-332
ERRα agonist. Exercise mimetic, body fat research (pre-clinical).
Pros
- · Injection-free oral research candidate versus retatrutide's injection burden.
- · Pan-ERR exercise-mimetic mechanism distinct from NNMT-inhibitor 5-Amino-1MQ.
Cons
- · No oral capsule form available unlike 5-Amino-1MQ.
- · Pre-clinical only; retatrutide has TRIUMPH Phase 3 data and imminent FDA filing.
5-Amino-1MQ (Oral)
NNMT inhibitor. Different metabolic pathway, oral form.
Pros
- · Oral capsule
Cons
- · Different target (NNMT)
See 5-Amino-1MQ (Oral) →
Retatrutide
GLP-1 / GIP / glucagon triple agonist. The strongest Phase 3 human data.
Pros
- · TRIUMPH Phase 3
- · FDA filing imminent
Cons
- · Injection burden
See Retatrutide →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 0 suppliers
No verified suppliers yet for this compound.
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
Research-only.
Initiation
Week 3–4
Research-only.
Signal emerges
Week 5–8
Research-only.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.
niche · IV
SLU-PP-332 · 5mg